Is EINECS 257-744-6 Safe in Breastfeeding

I am a breastfeeding mother and i want to know if it is safe to use EINECS 257-744-6? Is EINECS 257-744-6 safe for nursing mother and child? Does EINECS 257-744-6 extracts into breast milk? Does EINECS 257-744-6 has any long term or short term side effects on infants? Can EINECS 257-744-6 influence milk supply or can EINECS 257-744-6 decrease milk supply in lactating mothers?

• DrLact safety Score for EINECS 257-744-6 is 5 out of 8 which is considered Unsafe as per our analyses.
• A safety Score of 5 indicates that usage of EINECS 257-744-6 may cause serious side effects in breastfed baby.
• Our study of different scientific research indicates that EINECS 257-744-6 may cause moderate to high side effects or may affect milk supply in lactating mother.
• Our suggestion is to use safer alternate options rather than using EINECS 257-744-6 .
• It is recommended to evaluate the advantage of not breastfeeding while using EINECS 257-744-6 Vs not using EINECS 257-744-6 And continue breastfeeding.
• While using EINECS 257-744-6 Its must to monitor child for possible reactions. It is also important to understand that side effects vary largely based on age of breastfed child and time of medication in addition to dosage.
• Score calculated using the DrLact safety Version 1.2 model, this score ranges from 0 to 8 and measures overall safety of drug in lactation. Scores are primarily calculated using publicly available case studies, research papers, other scientific journals and publically available data.

EINECS 257-744-6, like other fibrates, decreases elevated blood lipids (triglycerides and cholesterol) by increasing the activity of lipases that catabolize triglyceride-rich lipoproteins and slightly decreasing cholesterol biosynthesis (Miller 1998). In general, fibrates have a discrete effect on the increase of high density lipoprotein (HDL) concentration and the reduction of low density lipoprotein (LDL). Since the last update we have not found published data in relation to breastfeeding. Its high binding to plasma proteins makes it unlikely it will pass into breast milk. Cholesterol levels in milk are very stable even in hypercholesterolemic women and are not severely affected by diet or nutritional status of the mother, suggesting that 3 is synthesized, at least in part, in the mammary gland (Lawrence 2016, p 289-90).It is not probable therefore, but it is not known if the fibrates are able to alter the lipid composition of the milk. Infants need to ingest large amounts of cholesterol, as it is critical to the proper development of the nervous system, cell membranes and is a precursor of several hormones and vitamins. Until there is more data in relation to breastfeeding, it is prudent to avoid using it, at least while breastfeeding exclusively. Suspending the pharmacological treatment of hyperlipidemia during breastfeeding is not likely to alter the long-term outcome of the disease, especially when breastfeeding can be considered therapeutic (Lawrence 2016, p.393). It is advisable to follow a lipid-lowering diet. In case of administering a fibrate during breastfeeding it is advisable to choose those with a shorter half-life: bezafibrate, gemfibrozil. Due to serious side effects in patients treated with EINECS 257-744-6, in most countries the product has been withdrawn from sale or restrictions have been imposed on its approved use.